- Home
- IEX vs MRNA Comparison
IEX vs MRNA Comparison
Compare IEX & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IEX | MRNA |
|---|---|---|
| Founded | 1987 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.6B | 11.5B |
| IPO Year | 1991 | 2018 |
Fundamental Metrics
Financial Performance| Metric | IEX | MRNA |
|---|---|---|
| Price | $178.52 | $29.82 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 14 |
| Target Price | ★ $196.00 | $33.25 |
| AVG Volume (30 Days) | 625.0K | ★ 9.8M |
| Earning Date | 02-03-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.59% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.32 | N/A |
| Revenue | ★ $3,421,300,000.00 | $2,232,000,000.00 |
| Revenue This Year | $6.31 | N/A |
| Revenue Next Year | $2.96 | $0.77 |
| P/E Ratio | $28.31 | ★ N/A |
| Revenue Growth | ★ 7.09 | N/A |
| 52 Week Low | $153.36 | $22.28 |
| 52 Week High | $228.88 | $48.92 |
Technical Indicators
Market Signals| Indicator | IEX | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 60.05 | 68.01 |
| Support Level | $173.03 | $26.90 |
| Resistance Level | $183.05 | $30.44 |
| Average True Range (ATR) | 3.17 | 1.19 |
| MACD | 0.37 | 0.59 |
| Stochastic Oscillator | 58.89 | 94.55 |
Price Performance
Historical ComparisonAbout IEX IDEX Corporation
Idex manufactures pumps, flow meters, valves, and fluidic systems for customers in a variety of end markets, including industrial, fire and safety, life science, and water. The firm's business is organized into three segments: fluid and metering technologies, health and science technologies, and fire and safety and diversified products. Based in Lake Forest, Illinois, Idex has manufacturing operations in over 20 countries and has over 7,000 employees. The company generated $3.3 billion in revenue in 2024.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.